Clinical context

Cataract surgery outcomes are not defined by best-corrected visual acuity alone. Refractive accuracy, vision at different distances, spectacle dependence, contrast sensitivity, dysphotopsia and procedural safety all matter. Corneal and macular status, capsular support, cataract density and IOL calculation also shape the final result. A statistically convincing average therefore still has to be interpreted against the characteristics of an individual eye.

What was studied

This retrospective series included 249 eyes of 249 patients after combined phacoemulsification and vitrectomy by one surgeon. One monofocal IOL, Akreos AO MI60, was implanted and refraction was measured after at least three months. Barrett Universal II, EVO 2.0, Kane and Ladas Super Formula were compared with SRK/T, Haigis, Holladay 1 and Hoffer Q, overall and by axial length. Eyes with silicone oil, retinal detachment, complications or previous refractive surgery were excluded.

How the evidence was produced

A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.

Key result Kane had the lowest MAE at 0.42 ± 0.34 D and MedAE at 0.33 D. EVO followed at 0.43 D, Barrett at 0.44 and Ladas at 0.45 D; Hoffer Q had the highest MAE at 0.58 D. Rates within ±0.50 D were 67.87% with Kane, 66.67% with EVO, 65.46% with Barrett and 65.86% with Ladas versus 55.02% with Hoffer Q. No formula showed a significant directional shift. Short-eye differences were not stable; most formulas except Hoffer Q performed acceptably in medium eyes. EVO and Barrett were more accurate in long eyes, and their absolute errors did not correlate with axial length.

How to interpret the result

Combined surgery does not create an inevitable myopic shift; disease, tamponade, biometry and lens position matter. Modern formulas reduced error, but the leader placed two thirds within ±0.50 D. In long eyes, comparing EVO and Barrett is reasonable.

The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.

Clinical applicability

This evidence is most useful as a basis for preoperative discussion and surgical planning. It helps identify which outcomes should be measured and which trade-offs should be explained to patients. The average effect should not be generalized to every IOL, technique or patient without checking eligibility criteria, surgeon experience, biometry, ocular comorbidity and duration of follow-up.

Limitations

This retrospective study used one IOL and surgeon. Diagnoses and tamponades varied, and subgroups were small. Twelve eyes used another biometer. Constants were not optimized, while other methods were unavailable. Requiring CDVA of 20/40 and excluding silicone oil limits generalizability. Verify subgroup sizes, diagnosis and gas outcomes, centering, RMSAE, attrition, complications, funding and external validation.

Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.

What to verify in the source

In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.